---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-088375"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2023-11-17T23:59:59+00:00"
generated_at: "2026-06-08T00:25:40.203466+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics faces Nasdaq delisting due to negative equity and bid price deficiency

## Summary
- Stockholders' equity as of Sep 30, 2023 was negative $3.379M, below Nasdaq's $2.5M minimum.
- Bid price has been below $1 per share for 30+ consecutive days, triggering a separate delisting notice.
- Hearing before Nasdaq Panel scheduled for Feb 1, 2024 to appeal both deficiencies.
- Company was previously under a Mandatory Panel Monitor until July 2024 for equity compliance.

## SEC filing metadata
- accession: 0001213900-23-088375
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2023-11-17T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390023088375/0001213900-23-088375-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390023088375/ea188641-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-088375
- JSON: https://secwatch.observer/filing/0001213900-23-088375.json
- Plain text: https://secwatch.observer/filing/0001213900-23-088375.txt

## Key facts
- Listing & Compliance Notices
  Allarity Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: November 16, 2023, we received a letter from Staff notifying us that the Company’s stockholders’ equity, as reported in its Quarterly Report on Form 10-Q for the period ended September 30, 2023 (the “Form 10-Q”), did not satisfy the continued listing requirement under Listing Rule 5550(b)(1) for The Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2.5 million. As reported on the Form 10-Q, the Company’s stockholders’ equity as of September 30, 2023 was ($3,379,000). Pursuant to the Staff letter , the Company is not eligible for a 180-calendar day
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023088375/0001213900-23-088375-index.htm
- Listing & Compliance Notices
  Allarity Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: October 27, 2023, we received a notification from Staff that it has determined that the bid price of our Common Stock has closed at less than $1 per share over the previous 30 consecutive business days, and did not comply with Listing Rule 5550(a)(2). As a result, our Common Stock will be delisted from The Nasdaq Capital Market. We have appealed such determination by requesting a hearing. The hearing has been scheduled for February 1, 2024 before a Nasdaq Hearing Panel (the “Panel Hearing”). On November 16, 2023, we received a letter from Staff notifying us that the Company’s stockholders’ equ
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023088375/0001213900-23-088375-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.